{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:12Z","timestamp":1707524652073},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,23]]},"DOI":"10.7759\/cureus.25243","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:25:08Z","timestamp":1653312308000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India"],"prefix":"10.7759","author":[{"given":"Michael L","family":"Anthony","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilotpal","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudheer","family":"Tale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunnumbrath","family":"Arathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalinee","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw P","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, et al.. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007, 2:706-714. 10.1097\/JTO.0b013e31812f3c1a","journal-title":"J Thorac Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst RS","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al.. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016, 387:1540-1550. 10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher L","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, et al.. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016, 387:1837-1846. 10.1016\/S0140-6736(16)00587-0","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger SN","year":"2015","unstructured":"Gettinger SN, Horn L, Gandhi L, et al.. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015, 33:2004-2012. 10.1200\/JCO.2014.58.3708","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al.. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015, 372:2018-2028. 10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-1833. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger DS","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al.. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022, 20:497-530. 10.6004\/jnccn.2022.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups","volume":"10","author":"Schmidt LH","year":"2015","unstructured":"Schmidt LH, K\u00fcmmel A, G\u00f6rlich D, et al.. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015, 10:e0136023. 10.1371\/journal.pone.0136023","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'Incecco A","year":"2015","unstructured":"D'Incecco A, Andreozzi M, Ludovini V, et al.. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015, 112:95-102. 10.1038\/bjc.2014.555","journal-title":"Br J Cancer"},{"key":"ref11","article-title":"Immunotherapy and lung cancer: programmed death 1 and its ligand as a target for therapy","author":"Kerr KM","year":"2018","unstructured":"Kerr KM, Laing GM. Immunotherapy and lung cancer: programmed death 1 and its ligand as a target for therapy. Precision Molecular Pathology of Lung Cancer. Cagle PT, Allen TC, Beasley MB et al. (ed): Springer, Switzerland; 2018. 2:257-273."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer A","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al.. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017, 389:255-265. 10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst RS","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, et al.. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014, 515:563-567. 10.1038\/nature14011","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2017.07.001","article-title":"Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India","volume":"31","author":"Vallonthaiel AG","year":"2017","unstructured":"Vallonthaiel AG, Malik PS, Singh V, et al.. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol. 2017, 31:56-61. 10.1016\/j.anndiagpath.2017.07.001","journal-title":"Ann Diagn Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.018","article-title":"Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes","volume":"50","author":"Yang CY","year":"2014","unstructured":"Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014, 50:1361-1369. 10.1016\/j.ejca.2014.01.018","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000526","article-title":"Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?","volume":"10","author":"Kerr KM","year":"2015","unstructured":"Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?. J Thorac Oncol. 2015, 10:985-989. 10.1097\/JTO.0000000000000526","journal-title":"J Thorac Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.05.005","article-title":"Immunotherapy in the treatment of non-small cell lung cancer","volume":"85","author":"Sundar R","year":"2014","unstructured":"Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 2014, 85:101-109. 10.1016\/j.lungcan.2014.05.005","journal-title":"Lung Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000458412","article-title":"Impact of PD-L1 expression in patients with surgically resected non-small-cell lung cancer","volume":"92","author":"Igawa S","year":"2017","unstructured":"Igawa S, Sato Y, Ryuge S, et al.. Impact of PD-L1 expression in patients with surgically resected non-small-cell lung cancer. Oncology. 2017, 92:283-290. 10.1159\/000458412","journal-title":"Oncology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu CY","year":"2011","unstructured":"Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011, 28:682-688. 10.1007\/s12032-010-9515-2","journal-title":"Med Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.05.001","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status","volume":"97","author":"Cha YJ","year":"2016","unstructured":"Cha YJ, Kim HR, Lee CY, Cho BC, Shim HS. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer. 2016, 97:73-80. 10.1016\/j.lungcan.2016.05.001","journal-title":"Lung Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.08.134","article-title":"Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment","volume":"11","author":"Huynh TG","year":"2016","unstructured":"Huynh TG, Morales-Oyarvide V, Campo MJ, et al.. Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol. 2016, 11:1869-1878. 10.1016\/j.jtho.2016.08.134","journal-title":"J Thorac Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12489","article-title":"High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases","volume":"67","author":"Mori S","year":"2017","unstructured":"Mori S, Motoi N, Ninomiya H, et al.. High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases. Pathol Int. 2017, 67:37-44. 10.1111\/pin.12489","journal-title":"Pathol Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.006","article-title":"Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma","volume":"11","author":"Takada K","year":"2016","unstructured":"Takada K, Okamoto T, Shoji F, et al.. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 2016, 11:1879-1890. 10.1016\/j.jtho.2016.06.006","journal-title":"J Thorac Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205362","article-title":"A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies","volume":"71","author":"Batenchuk C","year":"2018","unstructured":"Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. J Clin Pathol. 2018, 71:1078-1083. 10.1136\/jclinpath-2018-205362","journal-title":"J Clin Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","volume":"23","author":"Ratcliffe MJ","year":"2017","unstructured":"Ratcliffe MJ, Sharpe A, Midha A, et al.. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017, 23:3585-3591. 10.1158\/1078-0432.CCR-16-2375","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95843-immunoexpression-of-programmed-death-1-receptor-pd-1-and-programmed-death-ligand-1-pd-l1-in-non-small-cell-lung-carcinoma-and-its-correlation-with-other-clinicopathological-parameters-a-cross-sectional-study-from-north-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:32Z","timestamp":1707507752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95843-immunoexpression-of-programmed-death-1-receptor-pd-1-and-programmed-death-ligand-1-pd-l1-in-non-small-cell-lung-carcinoma-and-its-correlation-with-other-clinicopathological-parameters-a-cross-sectional-study-from-north-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.25243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}